About Bellicum
Bellicum is a company based in Houston (United States) founded in 2004. Bellicum has raised $137.53 million across 11 funding rounds from investors including HHS, RA Capital and Perceptive Advisors. The company has 108 employees. Bellicum operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Houston, United States
- Employees 108
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website bellicum.com
- Social LinkedIn X
- Annual Revenue$1.5 M (USD)-76as on Dec 31, 2022
- Total Equity Funding$137.53M (USD)
in 11 rounds
- Latest Funding Round$94.36M (USD), Series C
Sep 2014
- InvestorsHHS
& 10 more
- Employee Count108
Funding Insights of Bellicum
Bellicum has successfully raised a total of $137.53M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $94.36 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $137.53M
- Total Rounds 11
- Last Round Series C — $94.36M
- First Round $2.3M
(Oct 2007)
- Investors Count 11
Latest 10 of 11 funding rounds of Bellicum with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $94.36M | Series C | – | Jennison, RA Capital Management | – |
| Jan 2014 | $14.7M | Series B | – | – | |
| Apr 2013 | $1.24M | Grant | – | – | |
| Mar 2012 | $20M | Series B | – | Remeditex | – |
| Mar 2011 | $5.7M | Grant | – | – | |
| Oct 2010 | $1.18M | Series A | – | – | – |
| Oct 2009 | $4.5M | Series A | – | – | – |
| Oct 2009 | $1.25M | Debt – Conventional | – | – | – |
| Mar 2009 | $500,000 | Seed | – | – | – |
| Oct 2007 | $2.3M | Seed | – | – | – |
11 investors in total: 11 institutional.
Investors in Bellicum
Bellicum has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RA Capital and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
- | – | remeditex.com | - | |
Venture capital firm focused on healthcare startups | – | solasta-ventures.com | Boston, United States | |
- | – | emergingtechfund.com | - | |
Offers asset management and advisory for equities and fixed income portfolios. | 1969 | jennison.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Ridgeback Capital Management is engaged in personal financial planning and investment management. | 2011 | ridgebackcm.com | Bellaire, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Bellicum
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bellicum
12 people are tracked at Bellicum (4 in leadership, 5 in board & advisors, 3 in team); the tracked headcount is 108.
| Name | Role | Group |
|---|---|---|
Eric Yvon | Director CAR Program | Leadership |
Scott Jordan | Executive Director, Small Molecule Manufacturing | Leadership |
Damont E. | Director of Information Technology | Leadership |
Kurt Mickelson | Director - Clinical Supply Chain | Leadership |
Stephen R. Davis | Director | Board & advisors |
Reid M. Huber | Director | Board & advisors |
Jim Daly | Director | Board & advisors |
Judith Klimovsky | Director | Board & advisors |
Jon P. Stonehouse | Interim Chairman | Board & advisors |
Tigist A. | Quality Assurance Operations Manager | Team |
Mariam Khalil | Senior Research Associate | Team |
Bibi Obi | Senior Clinical Research Associate | Team |
Complete people profiles for Bellicum
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bellicum
4 dated milestones of Bellicum across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Bellicum is founded.
- Funding First funding round of $2.3M.
- Funding Latest funding round, Series C, of $94.4M.
- IPO Lists on the stock exchange (IPO).
Competitors of Bellicum
Bellicum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. |
Detailed competitors of Bellicum
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bellicum
The website of Bellicum (bellicum.com) receives about 1.8K visits a month and ranks #8,642,421 among all websites worldwide, #7,437 in Biotechnology and Pharmaceuticals.
- Monthly visits1.8K
▼ 0.8% vs previous month
- Global rank#8,642,421
among all websites
- Category rank#7,437
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.8
- Average visit35 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Bellicum. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| asteriasbiotherapeutics.com | 100% | – | – | View details | |
| argostherapeutics.com | 95% | – | – | View details | |
ipsen.ltd.uk | ipsen.ltd.uk | 92% | – | – | – |
| cyclacel.com | 92% | – | – | View details | |
| inovio.com | 92% | 11.7K | #1,670,423 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Bellicum
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Bellicum
Complete news archive for Bellicum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Bellicum
10 companies that operate in the same segment as Bellicum (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bellicum
Bellicum was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Bellicum is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Bellicum is a funded company, having raised a total of $137.53M across 11 funding rounds to date. The company's 1st funding round was a Seed of $2.3M, raised on Oct 2007.
Bellicum has 108 employees.
Annual revenue of Bellicum is $1.5M as on Dec 31, 2022.
Bellicum was founded in 2004 in Houston, United States, as a biotechnology firm focused on immunotherapy. CAR-T and TCR-based T cell therapies are developed for treating cancer and chronic infectious diseases. The pipeline includes BPX-501, an adjunct therapy for pediatric genetic disorders like SCID and hematologic cancers, as well as BPX-701, a TCR therapy targeting solid tumors with preferentially expressed antigens in melanoma. Operations center on advancing these cellular treatments.
Bellicum's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Bellicum has 11 investors. Key investors include HHS, RA Capital, Perceptive Advisors, Jennison Associates, and venBio.